These results suggest that a co-injection of apoA-I and CIGB-258 was more effective in preventing ROS production, even though an injection of either apoA-I or CIGB-258 was also effective in preventing oxidative stress in the presence of CML. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.